Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome

BACKGROUND AND OBJECTIVES: IVIg has been the preferred immunotherapy in stiff-person syndrome (SPS) based on a 3-month controlled trial, but whether it is also effective in inducing long-term benefits or arresting disease progression is unknown. The information is needed because SPS is a progressive...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Jessica, Dalakas, Marinos C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262284/
https://www.ncbi.nlm.nih.gov/pubmed/35798561
http://dx.doi.org/10.1212/NXI.0000000000200011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262284/
https://www.ncbi.nlm.nih.gov/pubmed/35798561
http://dx.doi.org/10.1212/NXI.0000000000200011

Ejemplares similares